Qu, Rihao
Kluger, Yuval
Yang, Junchen
Zhao, Jun
Hafler, David A.
Krause, Diane S.
Bersenev, Alexey
Bosenberg, Marcus
Hurwitz, Michael
Lucca, Liliana
Kluger, Harriet M.
Funding for this research was provided by:
National Cancer Institute (P50 CA121974, P50 CA121974, P50 CA121974)
National Institutes of Health (AI073748)
National Institutes of Health, United States (AI039671)
Article History
Received: 19 June 2022
Accepted: 28 November 2022
First Online: 14 December 2022
Declarations
:
: This study was conducted with approval of a Yale University Institutional Review Board after the patients provided consent for use of his clinical data and tumor and blood samples.
: The patient is deceased and cannot provide consent specifically for publication. Therefore, identifying information such as age, was removed.
: Dr. Hafler received research funding from Bristol-Myers Squibb, Sanofi, and Genentech for work unrelated to this project. He has been a consultant over the past 10 years for Bristol-Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Juno Therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme. Dr. Bersenev is a co-founder of Cell Trials Data, a co-founder and Managing Director of Cell BioEngines, and has received consultant fees from SES. Dr. Hurwitz has received consultant fees from Bristol Myer Squibb, CRISPR Therapeutics, Exelixis, Nektar Therapeutics, and Janssen, and research funding to Yale University from Iovance Therapeutics. Dr. Bosenberg is a consultant for Gennao Biosciences and Simcha Therapeutics. Dr. Harriet Kluger has received research funds (to Yale University) from Bristol-Myers Squibb, Merck and Apexigen and consulting fees from Iovance, Immunocore, Celldex, Array Biopharma, Merck, Elevate Bio, Instil Bio, Bristol-Myers Squibb, Clinigen, Shionogi, Chemocentryx, Calithera and Signatero.